Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ether doai
Reexamination Certificate
2006-01-10
2006-01-10
Kim, Vickie (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ether doai
Reexamination Certificate
active
06984665
ABSTRACT:
This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I)or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.
REFERENCES:
patent: 5352699 (1994-10-01), Jackson
patent: 5747059 (1998-05-01), Korsgaard et al.
patent: 5750576 (1998-05-01), DeGregorio et al.
patent: 5912273 (1999-06-01), Degregorio et al.
patent: 6037379 (2000-03-01), Härkönen et al.
patent: 6245819 (2001-06-01), Halonen et al.
patent: 2001/0034340 (2001-10-01), Pickar
patent: 0 664 124 (1995-07-01), None
patent: 1 125 582 (2001-08-01), None
patent: WO 96/07402 (1996-03-01), None
patent: WO 97/32574 (1997-09-01), None
patent: WO 01/54699 (2001-08-01), None
patent: WO 02/07718 (2002-01-01), None
K.C. Baynes et al., “Selective oestrogen receptor modulatros: a new paradigm for HRT,” Curr Opin Obstet Gynecol 10(3):189-192, Jun. 1998.
M.W. DeGregorio et al., “Hormone replacement therapy and breast cancer: revisiting the issues,” J Am Pharm Assoc 38(6):738-744, Nov.-Dec. 1998, (online abstract).
L. Kangas, “Biochemical and pharmacological effects of toremifene metabolites,” Cancer Chemother Pharmacol 27:8-12, 1990, XP 000675248.
M.M. Kennedy, “Tamoxifen and the endometrium: review of 102 cases and comparison with HRT-related-and non-HRT-related endometrial pathology,” Int J Gynecol Pathol 18(2):130-137, Apr. 1999 (online abstract).
B.H. Mitlak et al., “Selective Estrogen Receptor Modulators,” Drugs 57(5):653-663, May 1999.
Q. Qu et al., “Selective Estrogenic Effects of a Novel Tripheylethylene Compound, FC127la, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats,” Endocrinology 141(2):809-820, 2000 (online—20 pages).
M. Whitehead, “Treatment for menopausal and post-menopausal problems: present and future,” Baillieres Clin Obstet Gynaecol 10(3):515-530, Sep. 1996 (online abstract).
Blom Taru
Grönroos Paula
Halonen Kaija
Härkönen Pirkko
Hormos Medical Corporation
Kim Vickie
Rothwell Figg Ernst & Manbeck
LandOfFree
Methods for the inhibition of atrophy or for treatment or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the inhibition of atrophy or for treatment or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the inhibition of atrophy or for treatment or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3525924